Telix Pharmaceuticals Limited (TLX)
(Real Time Quote from BATS)
$11.77 USD
-0.20 (-1.67%)
Updated Aug 7, 2025 02:00 PM ET
4-Sell of 5 4
D Value B Growth A Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
TLX 11.77 -0.20(-1.67%)
Will TLX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for TLX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TLX
All You Need to Know About Telix Pharmaceuticals Limited (TLX) Rating Upgrade to Buy
Telix Shares May Gain on the Distribution Deal With Cardinal Health
TLX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Telix Pharmaceuticals Limited (TLX) Upgraded to Buy: What Does It Mean for the Stock?
What Makes Telix Pharmaceuticals Limited (TLX) a Good Fit for 'Trend Investing'
Other News for TLX
Telix Pharmaceuticals: Assessing The Market's Pullback On SEC Inquiry
Telix H1 2025 Results: Investor Webcast Notification | TLX Stock News
Telix Pharmaceuticals Faces SEC Investigation: Shares Plummet | TLX stock news
12 Health Care Stocks Moving In Wednesday's Intraday Session
First Look: Abivax Soars, Apple and Google Face UK Probe